Table 1 Clinical registries and trials studying COVID-19 with cardiovascular implications
From: Cardiac involvement in the long-term implications of COVID-19
Registry, trial or drug name | NCT identifier |
|---|---|
Registries | |
Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases | NCT04375748 |
COLUMBIA CARDS: COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry | NCT04661657 |
CAPACITY-COVID: Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY | NCT04325412 |
PCHF-COVICAV: COVID-19 in Hospitalized Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: The Global PCHF-COVICAV Registry | NCT04390555 |
CORONA-VTE NET: COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications | NCT04535128 |
Trials examining natural history, imaging or biomarkers, with an emphasis on cardiac sequelae | |
Sequelae of Sars-CoV-2 Infections | NCT04442789 |
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury | NCT04340921 |
Right Ventricular Dysfunction in Ventilated Patients With COVID-19 | NCT04764032 |
Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children | NCT04420468 |
Myocardial Injury and Quality of Life After COVID-19 | NCT04794062 |
Prevalence of Perimyocarditis After Covid-19 Vaccine | NCT04865900 |
Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients | NCT04358952 |
Cardiac Dysfunction in Critically Ill Patients With COVID-19 | NCT04524234 |
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19 | NCT04397939 |
Cardiac Injury in COVID-19: a Pathology Study | NCT04367792 |
Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection | NCT04753762 |
MYocardial DOmmages Related to COVID-19 | NCT04498065 |
Acute Cardiovascular Events Triggered by COVID-19-Related Stress | NCT04368637 |
Cardiovascular Complications and COVID-19 (CovCardioVasc-Study) | NCT04335162 |
Cardiac COVID-19 Health Care Workers | NCT04413071 |
Mechanical Complications of Acute Myocardial Infarction During COVID-19 Pandemics | NCT04813692 |
EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19 | NCT04498091 |
Prevalence of Myocardial Scars on CMR After COVID-19 Infection | NCT04636320 |
One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia | NCT04501822 |
Cardiac anti-inflammatory therapy | |
Colchicine | NCT04416334, NCT04375202, NCT04350320, NCT04724629, NCT04367168, NCT04360980, NCT04359095, NCT04667780, NCT04492358, NCT04324463, NCT04381936, NCT04328480 |
Renin–angiotensin–aldosterone system inhibition | |
Ramipril | NCT04366050 |
Telmisartan | NCT04466241, NCT04359953, NCT04510662, NCT04355936 |
Losartan | NCT04643691, NCT04328012 |
Candesartan | NCT04351724 |
Spironolactone | NCT04643691 |
Angiotensin 1–7 | NCT04605887, NCT04633772 |
Antiplatelet or anticoagulant therapy | |
Aspirin | NCT04333407, NCT04365309, NCT04324463, NCT04381936 |
Clopidogrel | NCT04333407, NCT04409834 |
Rivaroxaban | NCT04333407, NCT04324463, NCT04351724, NCT04715295, NCT04662684, NCT04394377 |
Enoxaparin | NCT04406389, NCT04409834, NCT04508439, NCT04646655, NCT04394377 |
Unfractionated heparin | NCT04406389, NCT04409834, NCT04372589, NCT04394377 |
Fondaparinux | NCT04406389 |
Argatroban | NCT04406389 |
‘Therapeutic anticoagulation’ | NCT04444700, NCT04486508 |
Lipid-lowering therapy | |
Atorvastatin | NCT04333407, NCT04466241, NCT04380402, NCT04900155 |
Rosuvastatin | NCT04359095 |
Ezetimibe | NCT04900155 |
Omega 3/icosapent ethyl | NCT04553705, NCT04460651, NCT04505098, NCT04412018 |
Pulmonary hypertension and heart failure therapy | |
Ambrisentan | NCT04393246 |
Sildenafil | NCT04489446 |
Dapagliflozin | NCT04393246, NCT04350593 |
